scholarly journals n−3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study

2003 ◽  
Vol 77 (2) ◽  
pp. 319-325 ◽  
Author(s):  
Rozenn N Lemaitre ◽  
Irena B King ◽  
Dariush Mozaffarian ◽  
Lewis H Kuller ◽  
Russell P Tracy ◽  
...  
2014 ◽  
Vol 13 (6) ◽  
pp. 32-37
Author(s):  
M. N. Sin’kova ◽  
T. V. Pepelyaeva ◽  
L. K. Isakov ◽  
N. I. Tarasov ◽  
A. T. Teplyakov

Currently there is enough evidence for that the use of omega-3-faty acids compounds in ischemic heart disease is followed by the decrease of mortality, and the efficacy of this usage in multivessel coronary lesions after primary percutaneous intervention (PCI) has not been studied.Aim.To evaluate the efficacy of long-term intake of the omega-3-polyunsaturated fatty acids compounds on the course of ischemic heart disease at the background of multiple coronary lesion after primary PCI.Material and methods.Totally 101 patient included at the age of 35-70 y.o., who had underwent primary PCI for the myocardial infarction with ST elevation and multiple vessel lesion of coronary arteries. The patients were selected into 2 groups: 1 group (n=68) — conservative tactics with the standard pharmacotherapy; 2nd group (n=33) — Omacor was added to the standard therapy.Results.In 36 months of follow-up in the Omacor group there was significant decrease of repeated myocardial infarctions, decompensating heart failure, angina progression and rhythm disorders. In 2nd group patients during the 36-month follow-up a better antiischemic effect achieved with 80,9% decrease of angina from the baseline (p<0,047) and by 27,6% of the heart failure severity. The increase of exercise tolerance by the 6-minute walking test during 36 months was the highest in the 2nd group — by 65%.Conclusion.Long-term prescription of omega-3-polyunsaturated fatty acids in ST elevation myocardial infarction with multiple vessel coronary lesions after primary PCI leads to the improvement of clinical condition, which then leads to the increase of exercise tolerance and better life quality. 


2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Nicole R. Fowler ◽  
Amber E. Barnato ◽  
Howard B. Degenholtz ◽  
Angela M. Curcio ◽  
James T. Becker ◽  
...  

Background. Dementia and cardiovascular disease (CVD) are frequently comorbid. The presence of dementia may have an effect on how CVD is treated.Objective. To examine the effect of dementia on the use of four medications recommended for secondary prevention of ischemic heart disease (IHD): angiotensin-converting enzyme inhibitors, beta-blockers, lipid-lowering medications, and antiplatelet medications.Design. Retrospective analysis of data from the Cardiovascular Health Study: Cognition Study.Setting and Subjects. 1,087 older adults in four US states who had or developed IHD between 1989 and 1998.Methods. Generalized estimating equations to explore the association between dementia and the use of guideline-recommended medications for the secondary prevention of IHD.Results. The length of follow-up for the cohort was 8.7 years and 265 (24%) had or developed dementia during the study. Use of medications for the secondary prevention of IHD for patients with and without dementia increased during the study period. In models, subjects with dementia were not less likely to use any one particular class of medication but were less likely to use two or more classes of medications as a group (OR, 0.60; 95% CI, 0.36–0.99).Conclusions. Subjects with dementia used fewer guideline-recommended medications for the secondary prevention of IHD than those without dementia.


2021 ◽  
Vol 10 (6) ◽  
Author(s):  
Neil K. Huang ◽  
Petra Bůžková ◽  
Nirupa R. Matthan ◽  
Luc Djoussé ◽  
Calvin H. Hirsch ◽  
...  

Background Significant associations have been reported between serum total nonesterified fatty acid (NEFA) concentrations and coronary heart disease (CHD) mortality and incident nonfatal myocardial infarction (MI) in some prospective cohort studies. Little is known about whether individual or subclasses (saturated, polyunsaturated [n‐6 and n‐3], and trans fatty acids) of serum NEFAs relate to CHD mortality and nonfatal MI. Methods and Results CHS (Cardiovascular Health Study) participants (N=1681) who had no history of MI, angina, or revascularization or were free of MI at baseline (1996–1997) were included. NEFAs were quantified using gas chromatography. Cox regression analysis was used to evaluate associations of 5 subclasses and individual NEFAs with CHD composite (CHD mortality and nonfatal MI), CHD mortality, and incident nonfatal MI. During a median follow‐up of 11.7 years, 266 cases of CHD death and 271 cases of nonfatal MI occurred. In the fully adjusted model, no significant associations were identified between individual NEFA and CHD composite. Exploratory analyses indicated that lauric acid (12:0) was negatively associated (hazard ratio [HR], 0.76; 95% CI, 0.59–0.98; P =0.0328) and dihomo‐γ‐linolenic acid (20:3n‐6) was positively associated with CHD mortality (HR, 1.34; 95% CI, 1.02–1.76; P =0.0351). Elaidic acid (18:1n‐7 t ) was positively associated with incident nonfatal MI (HR, 1.46; 95% CI, 1.01–2.12; P =0.0445). No significant associations were observed for NEFA subclass and any outcomes. Conclusions In CHS participants, 2 NEFAs, dihomo‐γ‐linolenic and elaidic acids, were positively associated with CHD mortality and nonfatal MI, respectively, suggesting potential susceptibility biomarkers for risks of CHD mortality and nonfatal MI.


Author(s):  
Jyrki K. Virtanen ◽  
David S. Siscovick ◽  
Rozenn N. Lemaitre ◽  
William T. Longstreth ◽  
Donna Spiegelman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document